AI Article Synopsis
- The study focused on creating and analyzing the behavior of bifendate (DDB) liposomes through a specific preparation method and tested them in live mice and rats.
- Key findings include a liposome diameter of about 323 nm with a high encapsulation efficiency of over 91%, showing significantly better performance than the free drug solution in plasma circulation and liver delivery.
- The liposomal formulation demonstrated a mean residence time in plasma that was 3.72 times longer than the solution and delivered about 2.57 times more DDB to the liver, suggesting its potential as a superior alternative to existing DDB preparations.
Article Abstract
The purpose of this study was to develop and study the behaviors of bifendate (DDB) liposome in vivo. DDB liposome was prepared by the rotary evaporationextrusion method. The particle size, zeta-potential, encapsulation efficiency (EE), and in vitro drug release from liposome were determined and the in vivo studies were tested in mice and rats. The concentrations of DDB in plasma and liver at different sampling time points were determined by RP-HPLC. The liver concentration-time curves of DDB liposome and free drug solution in mice were determined, and the pharmacokinetic parameters in rats and mice were calculated and compared by statistical analysis. The average liposome diameter was 323 +/- 29 nm (n = 3) and the EE was 91.52 +/- 2.38%. There were significantly different parameters of k10 and area under the plasma concentrationtime curve (AUC(0-T)) between liposome and solution. The mean residence time (MRT(0-T)) in plasma of liposomal formulation was 3.72 times longer than that of solution. Compared with solution, DDB liposome delivered about 2.57 times higher DDB into liver. Thus, an optimum intravenous liposome formulation for DDB could be developed as an alternative to the commercial DDB preparations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10611861003639788 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disease-associated mutations in human BICD2 hyperactivate motility of dynein-dynactin.
J Cell Biol
October 2017
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA
Bicaudal D2 (BICD2) joins dynein with dynactin into a ternary complex (termed DDB) capable of processive movement. Point mutations in the gene have been identified in patients with a dominant form of spinal muscular atrophy, but how these mutations cause disease is unknown. To investigate this question, we have developed in vitro motility assays with purified DDB and BICD2's membrane vesicle partner, the GTPase Rab6a.
View Article and Find Full Text PDFNovel diphenyl dimethyl bicarboxylate provesicular powders with enhanced hepatocurative activity: preparation, optimization, in vitro/in vivo evaluation.
Int J Pharm
January 2012
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El Aini Street, 11562, Cairo, Egypt.
Diphenyl dimethyl bicarboxylate (DDB) is a hepatocurative agent used for treatment of various liver diseases. However, DDB therapeutic effectiveness is restricted by its low oral bioavailability that arises from its poor solubility and dissolution. Aiming at surmounting the aforementioned restrictions, DDB provesicular dry powders exemplified by proniosomes and proliposomes were prepared using film-deposition technique employing sorbitol as a carrier.
View Article and Find Full Text PDFDistribution of liposomal bifendate in liver following intravenous injection in mice.
J Drug Target
September 2010
Department of Pharmacy, Nanjing University of Traditional Chinese Medicine, Nanjing, People's Republic of China.
Article Synopsis
- The study focused on creating and analyzing the behavior of bifendate (DDB) liposomes through a specific preparation method and tested them in live mice and rats.
- Key findings include a liposome diameter of about 323 nm with a high encapsulation efficiency of over 91%, showing significantly better performance than the free drug solution in plasma circulation and liver delivery.
- The liposomal formulation demonstrated a mean residence time in plasma that was 3.72 times longer than the solution and delivered about 2.57 times more DDB to the liver, suggesting its potential as a superior alternative to existing DDB preparations.
Synthesis of a novel polymer bile salts-(polyethylene glycol)2000-bile salts and its application to the liver-selective targeting of liposomal DDB.
Drug Dev Ind Pharm
June 2010
Department of Pharmacy, Nanjing University of Traditional Chinese Medicine, Nanjing, PR China.
Purpose: The objective of this study was to achieve a sustained and targeted delivery of liposome to the liver, by modifying the phospholipid [phosphatidylcholine (PC)/cholesterol (10 : 1) liposomes with a novel polymer bile salts-(polyethylene glycol)(2000)-bile salts (BP(2)B).
Methods: First, we generated a novel BP(2)B by N,N'-dicyclohexylcarbodiimide/4-dimethylaminopyridine esterification method and confirmed by Fourier transform infraredand (1) H-NMR spectra. Second, we prepared the BP(2)B-modified liposomes (BP(2)BL) that included BP(2)B, and the effect of the weight ratios of BP(2)B/PC on entrapment efficiency was investigated and BP(2)B/PC = 3% (w/w) was determined as the optimum ratio for the 4,4'-dimethoxy-5,6,5',6'-bi (methylenedioxy)-2,2'-bicarbomethoxybiphenyl liposomes.
Schisandrin B protects against myocardial ischemia-reperfusion injury by enhancing myocardial glutathione antioxidant status.
Mol Cell Biochem
June 1999
Department of Biochemistry, The Hong Kong University of Science and Technology, PR China.
The effects of Schisandrin B (Sch B) and dimethyl-4,4'-dimethoxy-5,6,5',6'dimethylene-dioxy-biphenyl-2,2'-+ ++bicarboxylate (DDB) treatment on myocardial ischemia-reperfusion (IR) injury in isolated perfused rat hearts were examined under both in vitro and ex vivo conditions. In vitro administration of liposome-entrapped Sch B or DDB during reperfusion did not protect against myocardial IR injury, whereas ascorbic acid or Trolox supplemented perfusate produced protective effect, as evidenced by the significant decrease in the extent of lactate dehydrogenase leakage as well as an improvement in contractile force recovery. Myocardial protection afforded by N-acetyl-L-cysteine supplemented perfusate was not accompanied by the enhancement in contractile force recovery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!